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Introduction
Over the last year, governmental responses to the Coro-
navirus disease (COVID-19) crisis have generated significant 
attention and deliberation in terms of public services, the 
experience and lessons learnt from various restrictions, and 
ideas for approaching possible future pandemics. Indeed, the 
question of how to mitigate for what is likely the now endemic 
nature of COVID-19, and the subsequent health implications 
this brings, is increasingly prevalent among both political and 
civic discourse. One of the main conclusions reached by many 
is that although initial approaches to managing the COVID-19 
crisis focused on primary health measures, there are clearly 
significant economic implications in the short and long term 
that must be considered. Whilst various lockdown measures 
necessitated improved public engagement, understanding, 
and compliancy in order to successfully, if perhaps temporar-
ily, mitigate excess mortality in comparison to taking no ac-
tion, significant differences of view now exist on how best to 
manage the crisis. This is partially explained given we are like-
ly following an incremental process of moving from epidemic 
to endemic. Because of this, alongside the latest data on low 
seroprevalence levels [1] and the emerging understanding of 
antibody reduction post-infection [2], a greater focus on indi-
vidual choices and health behaviours needs to be relocated 
within this emerging context. In truth, whilst initial efforts to 
combat COVID-19 necessarily involved a focus on emergen-
cy response, economic and social considerations seem to be 
gradually switching the focus to ongoing management of the 
disease. Much of the rationale for this management quite jus-
tifiably focuses on avoiding systemic overburden and poten-
tial collapse within health systems through various interven-
tions (i.e. social distancing, hygiene, and regional or national 
lockdowns), so that the Infection Fatality Rate (IFR) can be 
lowered through a combination of available Intensive Care 
Units (ICU) and, over time, both better treatments and the 
development of a successful vaccine. 
Given that efforts within most developed countries seem 
to be focused on this management of the disease to buy time, 
importantly, and in the context of physical activity, changes in 
policy are now being developed and actioned. Indeed, many 




expediency and the fact that politicians and policy makers are 
now having to walk a proverbial tightrope over health and eco-
nomic policy. To many, as COVID-19 moved from potential ep-
idemic, to global pandemic, and now endemic, an emphasis on 
the concurrent risk factors is warranted. Much subsequent and 
emerging health policy is now necessarily focused on dampen-
ing the transmission and spread of the disease through man-
aging behaviours, and many governments, in response to the 
COVID-19 crisis, have started to actively promote programmes 
and strategies that emphasise physical activity, weight loss, 
and good nutritional habits. This is in order to combat what are 
known as risk areas for COVID-19 patients, for instance, obe-
sity, poor cardiovascular fitness, diabetes, and other chronic 
health conditions, that place COVID-19 patients at higher rela-
tive risk of post-infection complications yet which can also be 
partially mitigated through healthy diet and exercise.
Strategies, such as the UK’s £2 billion package (announced 
in May 2020) to create more cycle and walkways, seek to im-
prove the resilience of health systems, and it is in this vein that 
we argue for a well-informed debate related to public health 
and the complex societal concerns regarding the use of Ana-
bolic-Androgenic Steroids (AAS) and Performance Enhancing 
Drugs (PEDS). This is because, outside of the non-COVID-19 
potential health problems that AAS use presents [3], figures 
on the prevalence of PED usage in the UK population are both 
significant and worrying. For instance, in 2016 Wales had an 
estimated number of 271,000 16-59-year olds who had re-
ported lifetime use of AAS [4], in a population that in 2017 
numbered 3,125,200 [5], a prevalence rate of 0.08%, equiva-
lent to 8,000 cases per 100,000 population. 
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tial impact that AAS use may have in terms of compromising 
immune responses in individuals who would not, without AAS 
use, be positioned in high risk groups. 
This is because in the context of personal choices regard-
ing AAS use, any subsequent medical intervention and sup-
port package that may have been exacerbated by damaged 
or lesser functioning immune systems will need to be consid-
ered in terms of economic impact and resource constraints, 
i.e. ICU availability and hospital bed spaces. In particular, AAS 
use likely has the potential, in a COVID-19 endemic world, of 
increasing medical interventions associated with increased in-
flammation and lowered auto-immune responses. A well-in-
formed public debate on AAS use then, should consider the 
emerging scientific evidence related to COVID-19 comorbid-
ities and low and high-risk populations, alongside existing 
medical evidence in the field of AAS use and immunosuppres-
sion. This commentary calls for new advisory bodies to be es-
tablished to provide a cost-benefit framework and scientific 
debate in order to potentially reposition government policy 
and governance arrangements in respect of approaches to 
controlling AAS use in both the context of sport (i.e. guide-
lines on bans) and recreational use.
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Our position on this matter is apparent in our previous re-
search and subsequent views related to AAS/PED use within 
sport [6-8]. Here, we argued against their use on both ethi-
cal, fundamentally through permanent morphological change 
which could leave an advantageous legacy, and health, 
through various known and unknown health detriments, 
grounds. In light of COVID-19, an infectious disease that char-
acteristically elicits immune responses that can lead to hyper-
inflammation, we revisit some of our polemic regarding AAS 
use in athletes and recreational capacities. Our rationale for 
doing so is in much part because of the need to discuss the 
potential for increased economic burden and, indeed, the ne-
cessity of maintaining or lowering IFR and reducing additional 
but preventable pressure on existing ICU resource. Alongside 
the accepted scientific evidence that outlines the precise 
health risks asso ciated with AAS and other PEDs [e.g. 3], the 
identification of AAS as immunosuppresors (thereby reducing 
immune cell number and function) has long been recognised. 
Specifically, the work of Fuji, Nawa, Tsuchiya, Matsuno, Fu-
kumoto, Fukuda, and Kotani [9], for instance, demonstrated 
how mammalian (mice) responses to elevated testosterone 
confirmed suppressive activity on the immune system, and 
Kanda, Tsuchida, and Tamaki’s [10] in vitro study using hu-
man peripheral blood mononuclear cells (PBMC) found that 
exposure to single dose of additional testosterone inhibited 
immunoglobin G (IgG) and immunoglobin M (IgM) antibod-
ies production indicating adverse results for immune system 
function.
Some contrast to these findings can be found in Cala-
brese, Kleiner, Barna, Skibinski, Kirkendall, Lahita, and Lom-
bardo’s work [11]. Here, they used competitive bodybuilders 
who self-administered AAS and found that Natural Killer (NK) 
lymphocytes, which form part of the network of cells and 
molecules that comprise the immune system and work to-
gether to protect the body from infections, showed increased 
activity in AAS users. Crucially, however, they still support-
ed the wider literature stating that AAS use interferes with 
immune responsiveness. Considered together, the evidence 
strongly points to the deleterious and compromising effect 
of AAS on immune system response. Indeed, in their review 
of literature related to AAS effects on the immune system, 
Marshall-Gradisnik, Green, Brenu, and Weatherby [12] found 
overwhelming evidence showing animal and human exposure 
to AAS resulted in “adverse side effects on immune function 
and several other bodily systems” (p. 28).
Given the uncertainly of how the pandemic will eventu-
ate, mitigating COVID-19 morbidity and mortality by ensuring 
clinically vulnerable populations are less susceptible is war-
ranted, in terms of increasing cardiovascular function, reduc-
ing incidence and improving management of diabetes, and 
reducing obesity. This is particularly salient as, for instance, 
the UK currently identifies 2.2 million people as clinically ex-
tremely vulnerable (high risk) [13]. Subsequently, the enor-
mous pressure that this group (alongside the clinically vulner-
able - moderate risk group) presents is extremely challeng-
ing in terms of potential deaths even without possible ICU 
shortage and other, emerging, long-term health effects from 
COVID-19. Given this, we therefore posit that a natural pro-
gression to these lifestyle edicts and contemporary govern-
mental health advice and policy, should question the poten-
